What is LensGen?
Headquartered in Irvine, California, LensGen operates at the intersection of advanced optics and surgical medicine. The company is primarily recognized for the development of the Juvene fluid-optic intraocular lens, a breakthrough device designed to mimic the natural accommodative function of the human eye. By providing a dynamic solution for vision correction, LensGen aims to eliminate the reliance on spectacles for patients suffering from cataracts and presbyopia. The company's market position is defined by its commitment to clinical rigor and its ability to navigate the complex regulatory landscape of the medical device industry, effectively bridging the gap between laboratory innovation and patient-centric surgical outcomes.
How much funding has LensGen raised?
LensGen has raised a total of $31.9M across 3 funding rounds:
Private Equity
$950K
Series A
$21M
Debt
$10M
Private Equity (2013): $950K, investors not publicly disclosed
Series A (2017): $21M, investors not publicly disclosed
Debt (2020): $10M supported by HOYA Corporation
Key Investors in LensGen
HOYA Corporation
A global technology company specializing in high-tech medical products, including intraocular lenses and optical glass, with a strong focus on healthcare innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for LensGen?
With the recent influx of capital, LensGen is poised to transition from its current clinical-stage status toward broader commercial readiness. The strategic roadmap focuses on finalizing clinical trials and optimizing manufacturing processes for the Juvene platform. As the company scales, it will likely prioritize regulatory submissions and the establishment of strategic partnerships with global ophthalmic distributors. By leveraging its recent financing, LensGen is well-positioned to disrupt the intraocular lens market, offering a scalable, high-performance alternative to traditional monofocal and multifocal lenses, ultimately aiming to set a new standard in refractive surgery and patient quality of life.
See full LensGen company page
